We are committed to exploring the frontier of cell therapy, with a focus on allogeneic CAR-T.

We are committed to exploring the frontier of cell therapy, with a focus on allogeneic CAR-T.

Explore More

ABOUT

Bioheng Therapeutics

200 + Patients Treated with Our UCAR-T

A leading clinical-stage Universal CAR-T company

Bioheng Therapeutics is a clinical-stage company focused on allogeneic " off-the-shelf " universal CAR-T therapies. Founded in 2017, we aim to develop the world’s leading allogeneic cell therapy platforms and products to address some of the most challenging unmet needs.

 

In March 2022, Bioheng received IND approval for CTA101, the first UCAR-T IND in China.

 

In June 2021, our CD7-targeted UCAR-T, CTD40X, received Orphan Drug Designation (ODD) from the U.S. FDA for the treatment of T-ALL. This product is based on Bioheng's novel and proprietary UCAR-T technology platform - ANSWER® and has demonstrated excellent safety and efficacy in approximately 100 patients, with median persistence of around 45 days. We are progressing the global clinical trial for this promising pipeline.

Built upon ANSWER® platform, we are actively developing multiple UCAR-T pipelines. These programs have shown robust and extended allogeneic CAR-T persistence, presenting strong potential in autoimmune and oncology indications.

 

We're always trying our best to meet the unmet needs.

HISTORY OF

Bioheng

A clinical-stage allogeneic cell therapy biotech company

Fast UCAR-T clinical POC and enrollment

• Explored various UCAR-T designs in preclinical and clinical settings

• 200+ patients treated with Bioheng‘s allogeneic CAR-T

Leading in CD7 with expanding pipelines

• Treated the highest number of patients (~100) with CD7 UCAR-T since 2020

• Advanced design enabled the longest persistence and thus a durable response

Equipped with proprietary technology platforms

• Extended UCAR-T persistence: median ~45 days, up to 400 days

• Proprietary technology platforms: featuring ANSWER CAR® and Explored CAR®

2022.03

Obtained first universal CAR-T IND approval in China


2021.03

$80Mn USD Series B funded by Hillhouse, Decheng & Octagon


2020.01

Nanjing Cell Therapy Valley 7000銕 R&D Center & GMP facility


2019.02

100Mn RMB Series-A funded by Decheng Capital


2018.04

Angel financing by Simcere Pharmaceutical


Contact Us